News Releases

Date Title and Summary Additional Formats
Toggle Summary HTG to Highlight the Advantages of its Drug Discovery Engine at the 2023 BIO International Convention
TUCSON, Ariz. , May 18, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today announced that its management team will present the advantages of its proprietary drug discovery engine at the 2023
View HTML
Toggle Summary HTG Highlights the Advantages of Its Drug Discovery Engine
TUCSON, Ariz. , May 16, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today reported achievement of another technical milestone in its drug discovery business.
View HTML
Toggle Summary HTG Molecular Diagnostics Reports First Quarter 2023 Results and Provides Recent Business Highlights
TUCSON, Ariz. , May 10, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today reported financial results for the quarter ended March 31, 2023 and provided recent drug discovery business highlights.
View HTML
Toggle Summary HTG Provides Update on Drug Discovery Partnering Initiative
TUCSON, Ariz. , April 25, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today provided an update on partnering discussions for its drug discovery business unit.
View HTML
Toggle Summary HTG Announces Key First Quarter Milestone Achievements for Drug Discovery
TUCSON, Ariz. , April 18, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today announced the achievement of three significant drug discovery business milestones in the first quarter of 2023.
View HTML
Toggle Summary HTG Technology Featured in Numerous Scientific Posters at the AACR Annual Meeting April 16-19
TUCSON, Ariz. , April 06, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today announced there will be at least four scientific posters featuring its proprietary HTG EdgeSeq™ technology presented at the
View HTML
Toggle Summary HTG Provides a Year-End Update on its Drug Discovery Business and Attends LifeSci Partners 2023 Corporate Access Event
TUCSON, Ariz. , Jan. 09, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today provided an update on the progress of
View HTML
Toggle Summary HTG Announces Certain Preliminary 2022 Unaudited Financial Results
Preliminary full year 2022 unaudited revenue of $6.4 million Cash and cash equivalents of $12.2 million as of December 31, 2022 TUCSON, Ariz. , Jan. 06, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its
View HTML
Toggle Summary HTG Molecular Diagnostics Provides Highlights of its Second Event in Drug Discovery KOL Webcast Series
TUCSON, Ariz. , Dec. 28, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, provides here a summary of its second HTG
View HTML
Toggle Summary HTG Molecular Diagnostics Announces Closing of a $10 Million Public Offering
TUCSON, Ariz. , Dec. 23, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today announced the closing of its previously
View HTML